Thus, prior ipilimumab induction may trigger intra-tumoral recruitment of CD4+/CD8+ T cells from peripheral blood or tumor parenchyma switching tumor microenvironment from immune-excluded/desert to immune-inflamed status, so called from “cold” to “hot” status. Here, CD4 is linked to neoplasm.